ReviewBiosafety and health2024
Antimicrobial resistance containment in Africa: Moving beyond surveillance.
Review in Biosafety and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Protocols for genomic epidemiology and source attribution of enteric bacteria causing diarrhoeal disease across Africa.BMJ open · 2026Article
- Knowledge, attitudes and practices of smallholder dairy farmers on antimicrobial use in selected districts of Zambia: implications for antimicrobial stewardship.Frontiers in veterinary science · 2026Article
- Antimicrobial Resistance in Refugee Camps and Prisons: A Global Scoping Review of Primary Studies on Burden, Risk Factors, Surveillance, and Mitigation Strategies.Infection and drug resistance · 2026Review
- Epidemiology and predictors of multidrug-resistant Enterobacteriaceae in intensive care units of a tertiary hospital in Somalia: a five-year retrospective study (2019-2024).Frontiers in antibiotics · 2026Article
- Leveraging Artificial Intelligence to Advance Bioinformatics in Africa: Opportunities, Challenges, and Ethical Considerations in Combating Antimicrobial Resistance.Bioinformatics and biology insights · 2026Article
- Combating antimicrobial resistance in Africa: a strategic roadmap for surveillance, stewardship, and research.Frontiers in cellular and infection microbiology · 2025Review
- A Review of Medicinal Plants Used in the Management of Microbial Infections in Angola.Plants (Basel, Switzerland) · 2024Review
- Combating Antimicrobial Resistance in Africa: A Call for Multidimensional Strategies to a Growing Crisis.Ethiopian journal of health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, infections caused by drug-resistant pathogens constitute a significant challenge threatening therapeutic efforts. According to the World Health Organization (WHO), antimicrobial resistance (AMR) ranks among the top 10 global public health threats. Organisms with a high rate of multiple host adaptivity, significant genetic diversity (multiple lineages), high virulence factors, and genetic exchange have been isolated from various sources (humans, animals, and the environment) even without exposure to prior antibiotics. Till now, the source of AMR and how resistant clones are selected in the environment remain largely elusive, and potential anthropogenic transmission has been reported in different studies. Various drug-resistant pathogens, lineages, resistant clones, outbreak clusters, plasmid replicates, and genes that play a critical role in resistance dissemination have been identified. Maintenance of certain multidrug-resistant (MDR) determinants has also been shown to enhance or support the propagation of MDR. So far, significant advances have been made in understanding the burden of AMR. However, overcoming AMR requires a holistic approach, as there is no single approach with sufficient precision to curb the threat. While strengthening AMR surveillance efforts is essential, as we have shown, there is also a need to intensify efforts to strengthen therapeutic interventions, especially in priority regions such as Africa. Herein, we discussed the burden of AMR and the dissemination of AMR in humans, animals, and the environment (non-medical drivers). We further delved into the big questions on Africa and discussed how therapeutic interventions involving vaccines and other viable biomaterials could be pivotal in reducing the burden of AMR to the barest minimum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.